Transforming Growth Factor-beta Regulation of Ephrin Type-A Receptor 4 Signaling in Breast Cancer Cellular Migration

[1]  Ying E Zhang,et al.  Non-Smad Signaling Pathways of the TGF-β Family. , 2017, Cold Spring Harbor perspectives in biology.

[2]  Lin Zhang,et al.  Isolation, characterization, and in rats plasma pharmacokinetic study of a new triterpenoid saponin from Dianthus superbus , 2017, Archives of pharmacal research.

[3]  J. Lebrun,et al.  A dual prognostic role for the TGFβ receptors in human breast cancer. , 2016, Human pathology.

[4]  S. Burgos,et al.  CDK4 regulates cancer stemness and is a novel therapeutic target for triple-negative breast cancer , 2016, Scientific Reports.

[5]  J. Lebrun,et al.  The Retinoblastoma Tumor Suppressor Protein (pRb)/E2 Promoter Binding Factor 1 (E2F1) Pathway as a Novel Mediator of TGFβ-induced Autophagy* , 2015, The Journal of Biological Chemistry.

[6]  Zhonghu Bai,et al.  Breast cancer intrinsic subtype classification, clinical use and future trends. , 2015, American journal of cancer research.

[7]  D. Meiri,et al.  RhoGTPases - A novel link between cytoskeleton organization and cisplatin resistance. , 2015, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[8]  Morag Park,et al.  Breast cancer anti-estrogen resistance 3 inhibits transforming growth factor β/Smad signaling and associates with favorable breast cancer disease outcomes , 2014, Breast Cancer Research.

[9]  R. Sainsbury.  The development of endocrine therapy for women with breast cancer. , 2013, Cancer treatment reviews.

[10]  J. Lebrun,et al.  Activin and TGFβ regulate expression of the microRNA-181 family to promote cell migration and invasion in breast cancer cells. , 2013, Cellular signalling.

[11]  S. Rabbani,et al.  Cyclin D1 cooperates with p21 to regulate TGFβ-mediated breast cancer cell migration and tumor local invasion , 2013, Breast Cancer Research.

[12]  J. Lebrun,et al.  MicroRNA-584 and the Protein Phosphatase and Actin Regulator 1 (PHACTR1), a New Signaling Route through Which Transforming Growth Factor-β Mediates the Migration and Actin Dynamics of Breast Cancer Cells* , 2013, The Journal of Biological Chemistry.

[13]  J. Lebrun.  The Dual Role of TGFβ in Human Cancer: From Tumor Suppression to Cancer Metastasis , 2012, ISRN molecular biology.

[14]  A. Hata,et al.  Targeting the TGFβ signalling pathway in disease , 2012, Nature Reviews Drug Discovery.

[15]  J. Lebrun,et al.  A transcriptionally active pRb–E2F1–P/CAF signaling pathway is central to TGFβ-mediated apoptosis , 2012, Cell Death and Disease.

[16]  A. Hata,et al.  Targeting the TGFβ signalling pathway in disease , 2012, Nature Reviews Drug Discovery.

[17]  S. Rabbani,et al.  A novel function for p21Cip1 and acetyltransferase p/CAF as critical transcriptional regulators of TGFβ-mediated breast cancer cell migration and invasion , 2012, Breast Cancer Research.

[18]  Andreas Wicki,et al.  Molecular Oncology: Targeted therapies in breast cancer , 2013 .

[19]  M. Reiss,et al.  Luminal breast cancer metastasis is dependent on estrogen signaling , 2012, Clinical & Experimental Metastasis.

[20]  N. Bertos,et al.  Breast cancer - one term, many entities? , 2011, The Journal of clinical investigation.

[21]  Dana M. Brantley-Sieders,et al.  Eph/Ephrin Profiling in Human Breast Cancer Reveals Significant Associations between Expression Level and Clinical Outcome , 2011, PloS one.

[22]  X. Chen,et al.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. , 2011, The Journal of clinical investigation.

[23]  P. Dijke,et al.  The TGF-β/Smad pathway induces breast cancer cell invasion through the up-regulation of matrix metalloproteinase 2 and 9 in a spheroid invasion model system , 2011, Breast Cancer Research and Treatment.

[24]  V. Band,et al.  Histological, molecular and functional subtypes of breast cancers , 2010, Cancer biology & therapy.

[25]  Charles M Perou,et al.  Molecular stratification of triple-negative breast cancers. , 2010, The oncologist.

[26]  Jason I. Herschkowitz,et al.  Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer , 2010, Breast Cancer Research.

[27]  M. Reiss,et al.  Targeting the Transforming Growth Factor-β pathway inhibits human basal-like breast cancer metastasis , 2010, Molecular Cancer.

[28]  Elena B. Pasquale,et al.  Eph receptors and ephrins in cancer: bidirectional signalling and beyond , 2010, Nature Reviews Cancer.

[29]  J. Moffat,et al.  A role for the TGFβ-Par6 polarity pathway in breast cancer progression , 2009, Proceedings of the National Academy of Sciences.

[30]  Jennifer L. Cutter,et al.  EphA2 mediates ligand-dependent inhibition and ligand-independent promotion of cell migration and invasion via a reciprocal regulatory loop with Akt. , 2009, Cancer cell.

[31]  Raghu Kalluri,et al.  The basics of epithelial-mesenchymal transition. , 2009, The Journal of clinical investigation.

[32]  Cédric Leroy,et al.  Quantitative phosphoproteomics reveals a cluster of tyrosine kinases that mediates SRC invasive activity in advanced colon carcinoma cells. , 2009, Cancer research.

[33]  A. Nobel,et al.  Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  Ying E Zhang,et al.  Non-Smad pathways in TGF-β signaling , 2009, Cell Research.

[35]  J. Massagué,et al.  TGFβ in Cancer , 2008, Cell.

[36]  Ian O Ellis,et al.  Basal-like breast cancer: a critical review. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  Elena B Pasquale,et al.  Eph-Ephrin Bidirectional Signaling in Physiology and Disease , 2008, Cell.

[38]  Dana M. Brantley-Sieders,et al.  The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling. , 2008, The Journal of clinical investigation.

[39]  Xiang-Jiao Yang,et al.  Transforming growth factor-beta inhibits telomerase through SMAD3 and E2F transcription factors. , 2008, Cellular signalling.

[40]  L. Gibson,et al.  Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. , 2007, The Cochrane database of systematic reviews.

[41]  S. Narod,et al.  Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence , 2007, Clinical Cancer Research.

[42]  S. Saika,et al.  Snail is required for transforming growth factor-beta-induced epithelial-mesenchymal transition by activating PI3 kinase/Akt signal pathway. , 2007, Biochemical and biophysical research communications.

[43]  Raymond B. Runyan,et al.  TGFβ‐mediated RhoA expression is necessary for epithelial‐mesenchymal transition in the embryonic chick heart , 2006, Developmental dynamics : an official publication of the American Association of Anatomists.

[44]  A. Nobel,et al.  The molecular portraits of breast tumors are conserved across microarray platforms , 2006, BMC Genomics.

[45]  J. Massagué,et al.  Smad transcription factors. , 2005, Genes & development.

[46]  C. Stournaras,et al.  LIM-kinase 2 and Cofilin Phosphorylation Mediate Actin Cytoskeleton Reorganization Induced by Transforming Growth Factor-β* , 2005, Journal of Biological Chemistry.

[47]  J. Zavadil,et al.  TGF-beta and epithelial-to-mesenchymal transitions. , 2005, Oncogene.

[48]  A. Gown,et al.  Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma , 2004, Clinical Cancer Research.

[49]  S. Murphy,et al.  Cell-Type-Specific Activation of PAK2 by Transforming Growth Factor β Independent of Smad2 and Smad3 , 2003, Molecular and Cellular Biology.

[50]  R. Nahta,et al.  HER-2-targeted therapy: lessons learned and future directions. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[51]  Stephen W. Wilson,et al.  Eph/Ephrin Signaling Regulates the Mesenchymal-to-Epithelial Transition of the Paraxial Mesoderm during Somite Morphogenesis , 2003, Current Biology.

[52]  N. Mochizuki,et al.  EphA4-Mediated Rho Activation via Vsm-RhoGEF Expressed Specifically in Vascular Smooth Muscle Cells , 2003, Circulation research.

[53]  G. Krystal,et al.  Activin/TGF-β induce apoptosis through Smad-dependent expression of the lipid phosphatase SHIP , 2002, Nature Cell Biology.

[54]  K. Kullander,et al.  Mechanisms and functions of eph and ephrin signalling , 2002, Nature Reviews Molecular Cell Biology.

[55]  J. Thiery.  Epithelial–mesenchymal transitions in tumour progression , 2002, Nature Reviews Cancer.

[56]  C. Heldin,et al.  Transforming growth factor-beta-induced mobilization of actin cytoskeleton requires signaling by small GTPases Cdc42 and RhoA. , 2002, Molecular biology of the cell.

[57]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[58]  M. Greenberg,et al.  EphA Receptors Regulate Growth Cone Dynamics through the Novel Guanine Nucleotide Exchange Factor Ephexin , 2001, Cell.

[59]  H. Moses,et al.  Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. , 2001, Molecular biology of the cell.

[60]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[61]  R. Davis,et al.  Evidence for a Role of Rho-like GTPases and Stress-activated Protein Kinase/c-Jun N-terminal Kinase (SAPK/JNK) in Transforming Growth Factor β-mediated Signaling* , 1997, The Journal of Biological Chemistry.

[62]  H. Beug,et al.  TGF-beta1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. , 1996, Genes & development.

[63]  R. S. Eliot.  Lessons Learned and Future Directions , 2020, Responsibility of Higher Education Systems.

[64]  C. Aring,et al.  A CRITICAL REVIEW , 1939, Journal of neurology and psychiatry.